Opsumit and Atacand drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Opsumit (macitentan) and Atacand (candesartan cilexetil). Common drug interactions include dyspnoea among females and oedema peripheral among males.

The phase IV clinical study analyzes what interactions people have when they take Opsumit and Atacand. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Opsumit?

Opsumit has active ingredients of macitentan. eHealthMe is studying from 67,926 Opsumit users. Check the latest studies of Opsumit.

What is Atacand?

Atacand has active ingredients of candesartan cilexetil. It is often used in high blood pressure. eHealthMe is studying from 22,473 Atacand users. Check the latest studies of Atacand.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

16 people who take Opsumit and Atacand together, and have interactions are studied.

What are the common drug interactions of Opsumit and Atacand, by gender? *:

female:

Dyspnoea (difficult or laboured respiration)
Nausea (feeling of having an urge to vomit)
Oedema peripheral (superficial swelling)
Arthralgia (joint pain)
Blood potassium decreased
Cardiac failure acute
Cardiogenic shock (inadequate circulation of blood)
Cardiopulmonary failure (cessation of normal circulation of the blood due to failure of the heart to contract)
Decreased appetite
Dizziness

male:

Oedema peripheral (superficial swelling)
Abdominal discomfort
Hypoaesthesia (reduced sense of touch or sensation)
Hypotension (abnormally low blood pressure)
Influenza like illness
Injury
Lethargy (tiredness)
Nausea (feeling of having an urge to vomit)
Peripheral swelling
Peripheral vascular disorder

What are the common drug interactions of Opsumit and Atacand, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Abdominal discomfort
Arthralgia (joint pain)
Blood phosphorus increased
Dyspnoea (difficult or laboured respiration)
Epistaxis (bleed from the nose)
Fistula (an abnormal connection or passageway between two)
Haemoglobin decreased
Headache (pain in head)
Heart rate increased
Hypoaesthesia (reduced sense of touch or sensation)

50-59:

n/a

60+:

Dyspnoea (difficult or laboured respiration)
Oedema peripheral (superficial swelling)
Fatigue (feeling of tiredness)
Fluid retention (an abnormal accumulation of fluid in the blood)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Haemorrhagic anaemia (anaemia due to excessive bleeding)
Hypoxia (low oxygen in tissues)
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
Pneumonia
Respiratory distress (difficulty in breathing)

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 12 people, 75.00%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 2 people, 12.50%
Arteriosclerosis Coronary Artery (thickening and hardening of arteries- coronary artery): 2 people, 12.50%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Opsumit and Atacand?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously